Document is current
Any future updates will be listed below
-
Authors
Tkatchenko, Tatiana V.
Shah, Rupal L.
Nagasaki, Takayuki
Tkatchenko, Andrei V.
-
Funding
Funding for this research was provided by:
National Institutes of Health (P30EY019007, Core Support for Vision Research received by the Department of Ophthalmology, Columbia University, R01EY023839)
Research to Prevent Blindness (Unrestricted funds received by the Department of Ophthalmology, Columbia University)
- License Information
-
More Information
Article History
Received: 14 May 2019
Accepted: 22 July 2019
First Online: 30 July 2019
Ethics approval and consent to participate
: Mice were obtained from the Jackson Laboratory (Bar Harbor, ME) and were maintained as an in-house breeding colony. All procedures adhered to the Association for Research in Vision and Ophthalmology (ARVO) statement on the use of animals in ophthalmic and vision research and were approved by the Columbia University Institutional Animal Care and Use Committee. Animals were anesthetized via intraperitoneal injection of ketamine (90 mg/kg) and xylazine (10 mg/kg) and were euthanized using CO<sub>2</sub> followed by cervical dislocation.All human studies were approved by the relevant institutional review boards and/or medical ethics committees and conducted according to the Declaration of Helsinki. All CREAM participants provided written informed consent. The UK Biobank received ethical approval from the National Health Service National Research Ethics Service (reference 11/NW/0382).
: Not applicable.
: AVT is a named inventor on two US patent applications related to the development of a pharmacogenomics pipeline for anti-myopia drug development. The remaining authors declare that they have no competing interests.
